Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Lenacapavir: First Approval.

Drugs·2023
Same author

Correction to: Ozanimod: A Review in Ulcerative Colitis.

Drugs·2022
Same author

Ozanimod: A Review in Ulcerative Colitis.

Drugs·2022
Same author

Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism.

Paediatric drugs·2022
Same author

Nivolumab Plus Relatlimab: First Approval.

Drugs·2022
Same author

Risdiplam: A Review in Spinal Muscular Atrophy.

CNS drugs·2022
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Aug 24, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.4K

Lenacapavir: First Approval.

Julia Paik1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|October 22, 2022
PubMed
Summary
This summary is machine-generated.

Lenacapavir is a new long-acting HIV-1 capsid inhibitor approved in the EU. This groundbreaking treatment offers a bi-annual injection option for multi-drug resistant HIV-1 infection.

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.4K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K

Related Experiment Videos

Last Updated: Aug 24, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.4K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.4K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • Human immunodeficiency virus type 1 (HIV-1) remains a significant global health challenge.
  • Multi-drug resistant (MDR) HIV-1 strains necessitate novel therapeutic strategies.
  • Lenacapavir represents a new class of antiretroviral agents targeting the HIV-1 capsid.

Purpose of the Study:

  • To summarize the key developmental milestones of lenacapavir.
  • To highlight the regulatory pathway leading to its first approval.
  • To provide an overview of lenacapavir's mechanism of action and formulation.

Main Methods:

  • Review of preclinical and clinical development data.
  • Analysis of regulatory submissions and approvals.
  • Description of lenacapavir's formulation (oral tablet, injectable solution).

Main Results:

  • Lenacapavir is a long-acting capsid inhibitor for HIV-1.
  • It offers a bi-annual subcutaneous injection for sustained drug delivery.
  • Received first EU approval in August 2022 for adults with MDR HIV-1.

Conclusions:

  • Lenacapavir's development marks a significant advancement in HIV-1 treatment.
  • The long-acting formulation provides a new option for patients with limited treatment alternatives.
  • This approval paves the way for broader clinical application in managing HIV-1 infection.